Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis

References

• American Cancer Society. Cancer facts & figures 2015. American Cancer Society, 2015. Available at: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf [Last accessed 16 August 2008]
   Google Scholar
• Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975–2013. Bethesda, MD: National Cancer Institute, 2016. Available at: http://seer.cancer.gov/csr/1975_2013/ [Last accessed 14 September 2016]
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707-16
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13
   Google Scholar
• Partridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014;32:3307-29
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Breast cancer, version 1.2016. Fort Washington (PA): National Comprehensive Cancer Network, 2015
   Google Scholar
• Ibrance (palbociclib) prescribing information. New York, NY: Pfizer Inc., 2016. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207103s002lbl.pdf [Last accessed 14 September 2016]
   Google Scholar
• Finn RS, Martin M, Rugo HS, et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC). J Clin Oncol 2016;34:abstr 507
   Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425-39
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84
   PubMed Web of Science ®Google Scholar
• NICE. The guidelines manual. National Institute for Health and Care Excellence; 2012. Available at: http://www.nice.org.uk/article/PMG6/chapter/1%20Introduction [Last accessed 16 October 2015]
   Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71
   PubMed Web of Science ®Google Scholar
• Cope S, Jansen JP. Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making. BMC Med Res Methodol 2013;13:147
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions, version 5.1.0. The Cochrane Collaboration, 2011. Available from http://www.handbook.cochrane.org
   Google Scholar
• Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373:209-19
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 2001;19:2596-606
   PubMed Web of Science ®Google Scholar
• Cameron C, Coyle D, Richter T, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open 2014;4:e004301
   PubMed Web of Science ®Google Scholar
• Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR + breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013;30:870-84
   PubMed Web of Science ®Google Scholar
• Campos S, Guastalla JP, Subar M, et al. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009;9:39-44
   PubMed Web of Science ®Google Scholar
• Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39:2318-27
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Allegra J, Bertino JR, et al. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol 1986;13(Suppl 4); 9-14
   PubMed Web of Science ®Google Scholar
• Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998;9:639-45
   PubMed Web of Science ®Google Scholar
• Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013;14:989-98
   PubMed Web of Science ®Google Scholar
• Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report for Faslodex (fulvestrant). Procedure No.: EMEA/H/C/000540/II/0018. 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000540/WC500098922.pdf [Last accessed 16 August 2004]
   Google Scholar